BS_G00FHF3Q
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 109.16557161629434
- age_years
- 13.904
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.575
- G2M_CHECKPOINT+0.505
- MYC_TARGETS_V1+0.433
- DNA_REPAIR+0.428
- MYC_TARGETS_V2+0.273
- MITOTIC_SPINDLE+0.232
- SPERMATOGENESIS+0.201
- UNFOLDED_PROTEIN_RESPONSE+0.126
- PANCREAS_BETA_CELLS+0.095
- PI3K_AKT_MTOR_SIGNALING+0.043
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.643
- INTERFERON_GAMMA_RESPONSE-0.599
- TNFA_SIGNALING_VIA_NFKB-0.587
- INFLAMMATORY_RESPONSE-0.585
- IL6_JAK_STAT3_SIGNALING-0.520
- ALLOGRAFT_REJECTION-0.500
- HYPOXIA-0.496
- IL2_STAT5_SIGNALING-0.478
- NOTCH_SIGNALING-0.475
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.467
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Y8D1F5WW | medulloblastoma | — | 0.991 |
| 2 | BS_GE2RVZE6 | medulloblastoma | — | 0.985 |
| 3 | BS_BSV07M7Z | medulloblastoma | — | 0.985 |
| 4 | BS_GNV89A5P | medulloblastoma | — | 0.982 |
| 5 | BS_HD4EJYE3 | medulloblastoma | — | 0.981 |
| 6 | BS_4PH1MBGR | medulloblastoma | — | 0.980 |
| 7 | BS_TYAYZ9ZW | medulloblastoma | — | 0.978 |
| 8 | BS_EFE4YEK3 | medulloblastoma | — | 0.977 |
| 9 | BS_HF3RNN2T | medulloblastoma | — | 0.977 |
| 10 | BS_J8G4SH4Z | medulloblastoma | — | 0.976 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.575 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.505 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.433 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.428 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.273 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.232 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.201 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.126 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.095 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.043 | Inavolisib | — uncovered |